These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 21456887)
1. Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: a meta-analysis of randomized controlled trials among the Japanese population. Iwamoto J; Takeda T; Matsumoto H Curr Med Res Opin; 2011 Jun; 27(6):1141-8. PubMed ID: 21456887 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials. Iwamoto J; Matsumoto H; Takeda T Curr Med Res Opin; 2008 May; 24(5):1379-84. PubMed ID: 18384711 [TBL] [Abstract][Full Text] [Related]
3. Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. Nguyen ND; Eisman JA; Nguyen TV J Bone Miner Res; 2006 Feb; 21(2):340-9. PubMed ID: 16526127 [TBL] [Abstract][Full Text] [Related]
4. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. John Camm A Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
6. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Sebba AI Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature. Iwamoto J; Sato Y; Takeda T; Matsumoto H Drugs Aging; 2012 Mar; 29(3):191-203. PubMed ID: 22372723 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials. Iwamoto J; Matsumoto H; Takeda T Clin Drug Investig; 2009; 29(7):471-479. PubMed ID: 19499964 [TBL] [Abstract][Full Text] [Related]
9. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630 [TBL] [Abstract][Full Text] [Related]
10. Meta-analysis for the efficacy of bisphosphonates on hip fracture prevention. Tsuda T; Hashimoto Y; Okamoto Y; Ando W; Ebina K J Bone Miner Metab; 2020 Sep; 38(5):678-686. PubMed ID: 32236684 [TBL] [Abstract][Full Text] [Related]
11. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523 [TBL] [Abstract][Full Text] [Related]
12. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Harris ST; Reginster JY; Harley C; Blumentals WA; Poston SA; Barr CE; Silverman SL Bone; 2009 May; 44(5):758-65. PubMed ID: 19168160 [TBL] [Abstract][Full Text] [Related]
13. Effect of Oral Bisphosphonate Drug Holiday on Mortality Following Hip Fracture. Leung MTY; Turner JP; Marquina C; Ilomaki J; Tran T; Bell JS J Clin Endocrinol Metab; 2024 Oct; 109(11):2793-2801. PubMed ID: 38630464 [TBL] [Abstract][Full Text] [Related]
14. [Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women]. Yuan T; Li XL; Zhang CQ; Shi HP; Zeng BF Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(23):1620-2. PubMed ID: 19957509 [TBL] [Abstract][Full Text] [Related]
15. Long-term use of bisphosphonates in osteoporosis. Watts NB; Diab DL J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017 [TBL] [Abstract][Full Text] [Related]
16. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Epstein S; Jeglitsch M; McCloskey E Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464 [TBL] [Abstract][Full Text] [Related]
17. RETRACTED: Efficacy of bisphosphonates against hip fracture in elderly patients with stroke and Parkinson diseases: meta-analysis of randomized controlled trials. Zhang W; Zhu C; Sun M; Ge Y; Yan G J Stroke Cerebrovasc Dis; 2014; 23(10):2714-2724. PubMed ID: 25314942 [TBL] [Abstract][Full Text] [Related]
18. Oral bisphosphonates are associated with reduced mortality after hip fracture. Beaupre LA; Morrish DW; Hanley DA; Maksymowych WP; Bell NR; Juby AG; Majumdar SR Osteoporos Int; 2011 Mar; 22(3):983-91. PubMed ID: 21052642 [TBL] [Abstract][Full Text] [Related]
19. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538 [TBL] [Abstract][Full Text] [Related]
20. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. Rietbrock S; Olson M; van Staa TP QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]